Table 2.
Laboratory data, management of immunosuppression, treatment modalities, and outcomes of kidney transplant recipients hospitalized with COVID-19
| Variable | Value | n |
|---|---|---|
| Laboratory data | ||
| CRP, mg/l | 62 [27–114] | 186 |
| Procalcitonin, ng/ml | 0.20 [0.14–0.48] | 90 |
| Lymphocyte count, ×109/l | 0.66 [0.40–0.96] | 184 |
| Platelet count, ×109/l | 178 [145–238] | 188 |
| Thrombocytopenia <150 × 109/l | 54 (29) | 188 |
| SaO2 | 96 (91–98) | 176 |
| Creatinine, μmol/l | 176 [131–244] | 200 |
| Immunusuppression management | ||
| CNI withdrawal | 58 (28.7) | 202 |
| Antimetabolite withdrawal | 136 (70.8) | 192 |
| mTOR inhibitor withdrawal | 18 (62.1) | 29 |
| Belatacept withdrawal | 7 (46.7) | 15 |
| COVID-19 treatment modalities | ||
| Azithromycin | 71 (29.2) | 243 |
| Other antibiotics | 153 (63.0) | 243 |
| Antifungal drugs | 6 (2.5) | 243 |
| Remdesivir | 2 (0.8) | 243 |
| Lopinavir/ritonavir | 11 (4.5) | 243 |
| Oseltamivir | 6 (2.5) | 243 |
| Hydroxychloroquine | 60 (24.7) | 243 |
| Tocilizumab | 13 (5.3) | 243 |
| Outcome | ||
| Bacterial coinfection | 57 (23.5) | 243 |
| Viral coinfection | 5 (2.1) | 243 |
| Fungal coinfection | 6 (2.5) | 243 |
| Oxygen therapy | 152 (72.4) | 210 |
| Mechanical ventilation | 72 (29.6) | 243 |
| Vasopressor support | 27 (11.1) | 243 |
| Acute kidney injury | 106 (43.6) | 243 |
| Renal replacement therapy | 27 (11.1) | 243 |
CNI, calcineurin inhibitors; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; mTOR, mammalian target of rapamycin; SaO2, arterial oxygen saturation.
Data are expressed as median [interquartile range] or count (%), as appropriate, unless otherwise indicated. Laboratory tests were performed on admission.